ACS awards research and training grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society has approved funding for 93 research and training grants totaling $40,277,750 in the first of two grant cycles for 2019. The grants will fund investigators at 65 institutions across the U.S.; 86 are new grants while seven are renewals of previous grants. All the grants go into effect July 1, 2019.

Highlights of the current cycle:

  • Dirk Hockemeyer, University of California, will investigate the mechanism by which mutations in the telomerase gene result in cancer cell immortality and to what extent these mutations are driving melanoma progression. Telomerase mutations are found in 10-15% of all cancers and in 70% of melanomas.

  • Taru Muranen, Beth Israel Deaconess Medical Center, will utilize patient-derived pancreatic cancer organoids together with stromal cells to identify effective drug combinations that could enhance the effectiveness of current therapies in pancreatic cancer, one of the most lethal types of cancer

  • Daniel Wahl, University of Michigan, is studying the factors that make glioblastoma multiforme brain tumors resistant to radiation. The aim is to inhibit certain metabolic pathways that appear altered in cancer cells to make radiation treatments more effective.

  • Tyler Risom, Stanford University, will lead a project that seeks to identify which ductal carcinoma in situ tumors will progress to invasive breast cancer using a new microscope technology: Multiplexed Ion Beam Imaging, which allows 40+ distinct protein markers to be seen simultaneously within a single tumor image. The work has the potential to greatly reduce patient over-treatment and expand the availability of effective drugs for the patients that need it.

  • Avonne Connor, Johns Hopkins Bloomberg School of Public Health, will investigate the roles of tumor type, overall health status, and socioeconomic status on outcomes for African American and Hispanic breast cancer survivors.

Health Professional Training grants include:

  • Two new sites were awarded Training Grants in Clinical Oncology Social Work, University of Rochester and Thomas Jefferson University. Four other sites successfully renewed their existing support. The grants train second-year master’s students to provide psychosocial services to cancer patients and their families.

  • Twelve new grants to support doctoral study were awarded to ten oncology nurses and two oncology social workers. Matthew LeBlanc of Duke University will work to identify needs among a newly growing group of cancer survivors: those with multiple myeloma. New treatments have led to impressive survival gains. This extended survival comes at a cost; patients are on perpetual treatment as they consistently transition to new medications when previous therapies stop working. He expects that findings from the study will help direct future research, intervention development, and clinical practice.

The American Cancer Society Extramural Research program supports research and training in a wide range of cancer-related disciplines at more than 200 institutions. The program primarily funds early career investigators. In addition, the Extramural Research program focuses on needs that are unmet by other funding organizations.

The Council for Extramural Research also approved 101 grant applications for funding, totaling $47,290,250 that could not be funded due to budgetary constraints. These “pay-if” applications represent work that passed the Society’s multi-disciplinary review process but are beyond the Society’s current funding resources. They can be and often are subsidized by donors who wish to support research that would not otherwise be funded. In 2018, more than $7 million in additional funding helped finance 32 “pay-if” applications.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login